Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received separate clinical trial approvals from the National Medical Products Administration (NMPA) for two of its investigational drug candidates, SHR-A1912 and SHR-1826. These drugs will be assessed for their efficacy in treating B-cell non-Hodgkin’s lymphoma in combination with rituximab and advanced malignant solid tumors, respectively.
SHR-A1912: A Promising ADC for Lymphoma
SHR-A1912 is an antibody drug conjugate (ADC) that targets CD79b, a protein expressed on the surface of B-cells in non-Hodgkin’s lymphoma. The drug is designed to deliver a potent cytotoxic payload directly to cancer cells, potentially improving treatment outcomes for patients. Roche’s Polivy (polatuzumab vedotin) is currently the only comparable commercially available drug, making SHR-A1912 a significant contender in this therapeutic space.
SHR-1826: A Novel Treatment for Solid Tumors
SHR-1826 is a drug that can specifically bind to target antigens on the surface of tumor cells and is internalized into the cells to induce cell death. This innovative mechanism of action has the potential to offer a new treatment option for patients with advanced malignant solid tumors. According to Hengrui, no similar product has been approved for marketing anywhere, highlighting the novelty and potential impact of SHR-1826 in the oncology field.-Fineline Info & Tech
